Anticipated Growth in XDEMVY Sales, Sales Force Expansion, and Promising Pipeline Signal a Bright Future for TARS Pharmaceuticals
As we approach the end of the second quarter of 2024, TARS Pharmaceuticals (TARS) stands poised for significant growth, driven primarily by the performance of its newly launched XDEMVY eye drops for Demodex Blepharitis (DB). Based on our tracking scripts and conservative estimates, we anticipate a robust quarter that aligns well with management’s optimistic projections and the company’s strategic initiatives aimed at sustaining growth throughout the fiscal year.
Strong 2Q24 Performance Expected
Our tracking data for XDEMVY suggests that TARS Pharmaceuticals will deliver approximately 36,682 bottles to patients in the second quarter of 2024. This estimate is slightly conservative compared to the TRx (IQVIA) forecast of 40,310 bottles but aligns closely with management’s expectations of a quarter-over-quarter increase. In the previous quarters, the company saw 15,700 bottles distributed in 4Q23 and 26,000 in 1Q24, indicating a steady upward trajectory. This trend supports our confidence in projecting sales of $33.4 million for 2Q24, surpassing the Street’s estimate of $32.4 million.
Overcoming Summer Seasonality
Despite the typical summer slowdown due to holidays, vacations, and medical conferences, TARS Pharmaceuticals is well-prepared to maintain its growth momentum into the second half of 2024. The company has strategically planned to expand its sales force, adding 50 new representatives and leaders by the end of 3Q24. Additionally, potential direct-to-consumer (DTC) efforts are slated for 4Q24, which could further bolster sales and market penetration. We also anticipate gradual improvements in gross-to-net (G/N) adjustments, enhancing the overall financial performance.
Promising Pipeline Enhances Long-term Outlook
While XDEMVY remains the primary value driver for TARS Pharmaceuticals, the company’s pipeline should not be overlooked. TARS is preparing for FDA meetings in 2024 for several promising candidates: TP-03 for Meibomian Gland Disease (MGD), TP-04 for Rosacea, and TP-05 for Lyme Disease Prevention (LDP). All these programs have reported positive Phase 2 data and leverage the same active ingredient as XDEMVY, suggesting a strong potential for future approvals and market success.
Market Opportunity and Unmet Needs
XDEMVY addresses a significant unmet medical need, as there are currently no other approved treatments for Demodex Blepharitis. The market opportunity for this condition is substantial, akin to the dry eye disease (DED) market, which has seen considerable growth. With extensive clinical data supporting XDEMVY’s efficacy and safety, TARS Pharmaceuticals is well-positioned to capture a significant share of this burgeoning market.
Reiterating Positive Outlook
We reiterate our “Outperform” rating for TARS Pharmaceuticals with a price target of $61. Our sum-of-the-parts (SOTP) analysis attributes $58.5 per share to XDEMVY’s U.S. sales, with the remaining $2.5 per share reflecting cash and technology assets. This valuation is underpinned by our confidence in the company’s ability to meet and potentially exceed sales expectations, supported by strategic initiatives and a robust pipeline.
TARS Pharmaceuticals is on a promising trajectory with the successful launch and ongoing growth of XDEMVY. The company’s strategic sales expansion, coupled with potential direct-to-consumer initiatives and a strong pipeline, underscores a bright future. Investors should remain confident in TARS’ ability to achieve and sustain growth, driven by its commitment to addressing high unmet medical needs in ophthalmology, dermatology, and other disease areas. With no other approved treatment for Demodex Blepharitis and a large, growing market, XDEMVY is set to become a cornerstone of TARS Pharmaceuticals’ success in the coming quarters.
You might like this article:McDonald’s Q2 Earnings Miss Expectations as Same-Store Sales Decline
